MedTrace Logo

Sunitinib and Capecitabine for First Line Colon Cancer

NCT00961571 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-02-12

Study results available
· View outcomes & findings →

Summary

This study is for patients with metastatic colorectal cancer who have not been treated with chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and Sunitinib can be used together to improve progression-free survival in colorectal cancer.

All patients will take two medicines (Sunitinib and Capecitabine) by mouth every day until their cancer gets worse.

Conditions

Interventions

DRUG

sunitinib and capecitabine

Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Georgetown University

    lead OTHER

Principal Investigators

  • Aiwu Ruth He, MD · Georgetown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961571 on ClinicalTrials.gov